STALICLA utilizes a precision neuro medicine platform that combines multiomics, patient data, and AI to match individuals with neurodevelopmental disorders to tailored pharmacological treatments. The company focuses on addressing the biological complexity of conditions like Autism Spectrum Disorder, aiming to improve patient outcomes through personalized medicine.
Funding
$54.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SGFounders
Product
Problem
Current treatment approaches for neurodevelopmental disorders, such as Autism Spectrum Disorder (ASD), often fail to address the underlying biological complexity and heterogeneity of these conditions, leading to suboptimal patient outcomes. A lack of personalized treatment strategies results in many individuals not receiving the most effective pharmacological interventions.
Solution
STALICLA is developing a precision neuro medicine platform that leverages multiomics data, patient-specific information, and artificial intelligence to identify subgroups of individuals with neurodevelopmental disorders who are most likely to respond to targeted pharmacological treatments. The company's DEPI platform uses AI-driven systems biology to decipher the biological complexity of brain disorders and match patients to specific drug candidates. By focusing on patient phenotyping, STALICLA aims to advance personalized treatments that address the unique biological profiles of individuals with conditions like ASD and substance use disorders. This approach enables the rapid development of precise therapeutics, potentially improving patient outcomes through tailored interventions.
Target Audience
The primary target audience includes individuals with neurodevelopmental disorders, such as Autism Spectrum Disorder, and substance use disorders, as well as their families and healthcare providers seeking more effective and personalized treatment options.
Features
- DEPI (Drug Efficacy Prediction Instrument) platform utilizes multiomics data, patient data, and AI to predict drug response.
- Focus on identifying patient subgroups within neurodevelopmental disorders based on biological phenotypes.
- Clinical-stage treatment options for neuropsychiatric and neurodevelopmental disorders.
- STP1: Fixed-dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide) for ASD Phenotype 1, currently in Phase 2 trials.
- STP2 (SFX-01): Stabilized synthetic form of sulforaphane for ASD Phenotype 2, with Phase 1 data under evaluation for Phase 2 development.
- STP7 (Mavoglurant): Negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM) for ASD Phenotype 7 and cocaine use disorder (CUD), in Phase 3 trials for CUD in collaboration with NIDA.
- Discovery and Data Science Unit (DDS) applies AI-driven and systems biology approaches to patient datasets.